Safety and Efficacy of Vagus Nerve Stimulation in Fibromyalgia: A Phase I/II Proof of Concept Trial
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We performed an open-label Phase I/II trial to evaluate the safety and tolerability of vagus nerve stimulation (VNS) in patients with treatment-resistant fibromyalgia (FM) as well as to determine preliminary measures of efficacy in these patients. METHODS: Of 14 patients implanted with the VNS stimulator, 12 patients completed the initial 3-month study of VNS; 11 patients returned for follow-up visits 5, 8, and 11 months after start of stimulation. Therapeutic efficacy was assessed with a composite measure requiring improvement in pain, overall wellness, and physical function. Loss of both pain and tenderness criteria for the diagnosis of FM was added as a secondary outcome measure because of results found at the end of 3 months of stimulation. RESULTS: Side effects were similar to those reported in patients treated with VNS for epilepsy or depression and, in addition, dry mouth and fatigue were reported. Two patients did not tolerate stimulation. At 3 months, five patients had attained efficacy criteria; of these, two patients no longer met widespread pain or tenderness criteria for the diagnosis of FM. The therapeutic effect seemed to increase over time in that additional participants attained both criteria at 11 months. CONCLUSIONS: Side effects and tolerability were similar to those found in disorders currently treated with VNS. Preliminary outcome measures suggested that VNS may be a useful adjunct treatment for FM patients resistant to conventional therapeutic management, but further research is required to better understand its actual role in the treatment of FM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Connolly, S. J., Sheldon, R., Thorpe, K. E., Roberts, R. S., Ellenbogen, K. A., Wilkoff, B. L., Morillo, C., Gent, M., & for the VPS II Investigators (2003) · JAMA · doi:10.1001/jama.289.17.2224 · Cited by 500 · cited 1×
“But studies reporting that outcome were for episodic events – syncope (15) or angina (16) – very different conditions from one with chronic pain.”
BackgroundRussell, J. I., Mease, P. J., Smith, T. R., Kajdasz, D. K., Wohlreich, M. M., Detke, M. J., Walker, D. J., Chappell, A. S., & Arnold, L. M. (2008) · Pain · doi:10.1016/j.pain.2008.02.024 · Cited by 367
Cited by
A review of vagus nerve stimulation as a therapeutic intervention
Johnson, R. L., & Wilson, C. G. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s163248 · Cited by 562
“After 11 months, 7 of the patients had the minimum clinical difference (MCID+) in their pain symptoms for VNS to be considered effective.(56) Another chronic pain ailment that VNS shows promise in treating is migraine headaches.”
Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part III
Yuan, H., & Silberstein, S. D. (2016) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12649 · Cited by 381
Farmer, A. D., Strzelczyk, A., Finisguerra, A., Gourine, A. V., Gharabaghi, A., Hasan, A., Burger, A. M., Jaramillo, A. M., Mertens, A., Majid, A., et al. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.568051 · Cited by 355
Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part II
Yuan, H., & Silberstein, S. D. (2016) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12650 · Cited by 303
Toffa, D. H., Touma, L., El Meskine, T., Bouthillier, A., & Nguyen, D. K. (2020) · Seizure · doi:10.1016/j.seizure.2020.09.027 · Cited by 286
Metadata
- Authors
- Lange, G., Janal, M. N., Maniker, A., FitzGibbons, J., Fobler, M., Cook, D., & Natelson, B. H.
- Venue
- Pain Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-09
- Volume
- 12
- Issue
- 9
- Pages
- 1406-1413
- ISSN
- 1526-2375 (ISSN-L)
- 1526-4637
- OpenAlex
- W2147966530
- Cited by
- 116
- References
- 2
- FWCI
- 0.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.